Biodexa announces award of additional $3.0m grant from cprit to support registrational erapa phase 3 program in fap brings total cprit grant funding for erapa phase 3 program to $20.0m

May 22, 2025 biodexa announces award of additional $3.0m grant from cprit to support registrational erapa phase 3 program in fap brings total cprit grant funding for erapa phase 3 program to $20.0m biodexa pharmaceuticals plc (“biodexa” or the “company”) (nasdaq: bdrx), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced its collaboration partner, rapamycin holdings, inc. d/b/a emtora biosciences (“emtora”) has been awarded an additional grant of $3.0 million from the cancer prevention & research institute of texas (“cprit”). this award brings the total grant awarded by cprit to support the registrational phase 3 program of erapa in familial adenomatous polyposis (“fap”) to $20.0 million.
BDRX Ratings Summary
BDRX Quant Ranking